This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Grail said Thursday that Bob Ragusa will retire as CEO on June 1 and be replaced by Josh Ofman. Ofman joined Grail in 2019, initially working as chief of corporate strategy and external affairs before a series of promotions culminated in his appointment as the company’s president in 2021.  Ragusa announced his retirement weeks after a trial of Grail’s ...

文章核心观点 - Grail公司股价单日暴跌50% 创下历史最大单日百分比跌幅 尽管其财报业绩超出预期 但导致股价暴跌的直接原因是其癌症检测工具的一项临床试验结果令人失望 [1] 公司业绩与市场反应 - 公司财报业绩超出市场预期 但股价仍出现暴跌 [1] - 股价录得有记录以来最大的单日百分比跌幅 [1] 产品与研发进展 - Grail公司的Galleri血液测试旨在癌症出现症状前筛查多种癌症 [1] - 导致股价暴跌的主要原因是 一项评估其癌症检测工具的试验结果令人失望 [1]